hydroxyurea has been researched along with Cronkhite-Canada Syndrome in 1 studies
Cronkhite-Canada Syndrome: A nonfamilial polyposis syndrome that is characterized by the presence of diffuse gastrointestinal polyposis, DIARRHEA, and PROTEIN-LOSING ENTEROPATHY. It was first reported by Cronkhite and Canada in 1955.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Gounaris, E | 1 |
| Heiferman, MJ | 1 |
| Heiferman, JR | 1 |
| Shrivastav, M | 1 |
| Vitello, D | 1 |
| Blatner, NR | 1 |
| Knab, LM | 1 |
| Phillips, JD | 1 |
| Cheon, EC | 1 |
| Grippo, PJ | 1 |
| Khazaie, K | 1 |
| Munshi, HG | 1 |
| Bentrem, DJ | 1 |
1 other study available for hydroxyurea and Cronkhite-Canada Syndrome
| Article | Year |
|---|---|
Zileuton, 5-lipoxygenase inhibitor, acts as a chemopreventive agent in intestinal polyposis, by modulating polyp and systemic inflammation.
Topics: Animals; Colonic Neoplasms; Disease Models, Animal; Female; Humans; Hydroxyurea; Inflammatory Bowel | 2015 |